LIBIQE Trademark

Trademark Overview


On Thursday, January 23, 2020, a trademark application was filed for LIBIQE with the United States Patent and Trademark Office. The USPTO has given the LIBIQE trademark a serial number of 88771083. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 14, 2022. This trademark is owned by Eli Lilly and Company. The LIBIQE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
libiqe

General Information


Serial Number88771083
Word MarkLIBIQE
Filing DateThursday, January 23, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 14, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 19, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 28, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, February 14, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 14, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, June 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 11, 2021EXTENSION 2 GRANTED
Friday, June 11, 2021EXTENSION 2 FILED
Friday, June 11, 2021TEAS EXTENSION RECEIVED
Tuesday, December 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 21, 2020EXTENSION 1 GRANTED
Wednesday, December 2, 2020EXTENSION 1 FILED
Monday, December 21, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 2, 2020TEAS EXTENSION RECEIVED
Tuesday, July 14, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 19, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 19, 2020PUBLISHED FOR OPPOSITION
Wednesday, April 29, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, April 13, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 13, 2020ASSIGNED TO EXAMINER
Tuesday, January 28, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, January 27, 2020NEW APPLICATION ENTERED IN TRAM